基因编辑权威指南。
★
菜单
首页 学习 新闻
探索 技术 疾病 治疗方法 临床试验 企业 科学家 基因 研究 机构
医学之外 农业 伦理 投资 世界地图
学习与工具 从这里开始 术语表 A–Z 对比技术 时间线 列表与排名 AI 智能体 ★ 已保存 API
关于 关于我们 方法论 数据来源 编辑方针 联系我们 免责声明

引导视图
遗传学新手?浏览时我们会用简单易懂的语言为您解释每个术语,就在同一页面内,帮助随时可用。

专家观点
你已经了解生物学基础,只需内容本身,简洁明了,无额外解释。这是默认视图。

界面语言
浅色模式
A Cas13 enzyme cutting a strand of RNA

Technology · RNA targeting

CRISPR-Cas13

Targets RNA rather than DNA, so it can silence a gene's message without touching the genome itself.

Phase I RNAreversiblediagnostics
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

简单说明

Every other CRISPR system here goes after DNA, the permanent copy of the instructions. Cas13 goes after RNA, the working copies the cell makes from those instructions. Destroy the working copies and the protein stops being made, but the original is untouched. That means the effect wears off, which is sometimes exactly what you want: a treatment you can stop is safer than one you cannot.

深入了解

Cas13 (type VI) effectors are RNA-guided RNA endonucleases with two HEPN domains. Guided by a crRNA to a complementary transcript, Cas13 cleaves it, knocking down gene expression without altering genomic DNA. Like Cas12a it shows collateral activity, in this case against RNA, which is the basis of the SHERLOCK diagnostic platform. Catalytically dead Cas13 fusions enable programmable RNA base editing (REPAIR, RESCUE).

Why targeting RNA is different

A DNA edit is permanent by design: if it is wrong, it stays wrong. An RNA-targeting therapy has to be re-dosed, because the cell keeps making fresh transcripts, an inconvenience that doubles as a safety feature. It also means there is no risk of a heritable change and no double-strand break to repair.

The trade-off is that RNA targeting cannot fix anything. It reduces the amount of a protein being made. For conditions caused by a toxic protein that is useful; for conditions caused by a missing protein it is not.

Diagnostics

Cas13's collateral RNA cleavage powers SHERLOCK, which pairs isothermal amplification with a fluorescent reporter to detect specific nucleic-acid sequences at very low concentration, an approach deployed for viral detection including during the COVID-19 pandemic.

Clinical status

Clinical work is early. Programmes have explored RNA knockdown in the eye and in genetic disease, and Cas13's reversibility makes it attractive where a permanent change would be hard to justify. Off-target and collateral activity in human cells has been a recurring concern in the literature and is an active area of engineering.

Sources

Connected in CRISPR Decoded

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

与本页面相关的新闻

已自动匹配至本记录。每条条目均链接至其出版方。

仅供教育参考 本页面为参考资源,不构成医疗建议。研究进展和监管状态会发生变化;请查看上方的最后更新日期,并对重要信息进行核实,以所列主要来源为准。